Literature DB >> 28397615

Modifiable Risk Factors for the Spread of Klebsiella pneumoniae Carbapenemase-Producing Enterobacteriaceae Among Long-Term Acute-Care Hospital Patients.

Koh Okamoto1, Michael Y Lin1, Manon Haverkate2, Karen Lolans3, Nicholas M Moore3, Shayna Weiner1, Rosie D Lyles4, Donald Blom1, Yoona Rhee1, Sarah Kemble1, Louis Fogg5, David W Hines6, Robert A Weinstein1, Mary K Hayden1.   

Abstract

OBJECTIVE To identify modifiable risk factors for acquisition of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae (KPC) colonization among long-term acute-care hospital (LTACH) patients. DESIGN Multicenter, matched case-control study. SETTING Four LTACHs in Chicago, Illinois. PARTICIPANTS Each case patient included in this study had a KPC-negative rectal surveillance culture on admission followed by a KPC-positive surveillance culture later in the hospital stay. Each matched control patient had a KPC-negative rectal surveillance culture on admission and no KPC isolated during the hospital stay. RESULTS From June 2012 to June 2013, 2,575 patients were admitted to 4 LTACHs; 217 of 2,144 KPC-negative patients (10.1%) acquired KPC. In total, 100 of these patients were selected at random and matched to 100 controls by LTACH facility, admission date, and censored length of stay. Acquisitions occurred a median of 16.5 days after admission. On multivariate analysis, we found that exposure to higher colonization pressure (OR, 1.02; 95% CI, 1.01-1.04; P=.002), exposure to a carbapenem (OR, 2.25; 95% CI, 1.06-4.77; P=.04), and higher Charlson comorbidity index (OR, 1.14; 95% CI, 1.01-1.29; P=.04) were independent risk factors for KPC acquisition; the odds of KPC acquisition increased by 2% for each 1% increase in colonization pressure. CONCLUSIONS Higher colonization pressure, exposure to carbapenems, and a higher Charlson comorbidity index independently increased the odds of KPC acquisition among LTACH patients. Reducing colonization pressure (through separation of KPC-positive patients from KPC-negative patients using strict cohorts or private rooms) and reducing carbapenem exposure may prevent KPC cross transmission in this high-risk patient population. Infect Control Hosp Epidemiol 2017;38:670-677.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28397615     DOI: 10.1017/ice.2017.62

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  11 in total

1.  Impact of a mixed educational and semi-restrictive antimicrobial stewardship project in a large teaching hospital in Northern Italy.

Authors:  Daniele Roberto Giacobbe; Valerio Del Bono; Malgorzata Mikulska; Giulia Gustinetti; Anna Marchese; Federica Mina; Alessio Signori; Andrea Orsi; Fulvio Rudello; Cristiano Alicino; Beatrice Bonalumi; Alessandra Morando; Giancarlo Icardi; Sabrina Beltramini; Claudio Viscoli
Journal:  Infection       Date:  2017-08-30       Impact factor: 3.553

Review 2.  The Epidemiology, Evolution, and Treatment of KPC-Producing Organisms.

Authors:  Ann Marie Porreca; Kaede V Sullivan; Jason C Gallagher
Journal:  Curr Infect Dis Rep       Date:  2018-05-05       Impact factor: 3.725

3.  Carbapenemase-producing Enterobacteriaceae and Aeromonas spp. present in wastewater treatment plant effluent and nearby surface waters in the US.

Authors:  Dimitria A Mathys; Dixie F Mollenkopf; Sydnee M Feicht; Rachael J Adams; Amy L Albers; David M Stuever; Susan V Grooters; Gregory A Ballash; Joshua B Daniels; Thomas E Wittum
Journal:  PLoS One       Date:  2019-06-26       Impact factor: 3.240

4.  Risk factors and survival of patients infected with carbapenem-resistant Klebsiella pneumoniae in a KPC endemic setting: a case-control and cohort study.

Authors:  Astrid V Cienfuegos-Gallet; Ana M Ocampo de Los Ríos; Patricia Sierra Viana; Faiver Ramirez Brinez; Carlos Restrepo Castro; Gustavo Roncancio Villamil; Helena Del Corral Londoño; J Natalia Jiménez
Journal:  BMC Infect Dis       Date:  2019-10-07       Impact factor: 3.090

5.  A mathematical model and inference method for bacterial colonization in hospital units applied to active surveillance data for carbapenem-resistant enterobacteriaceae.

Authors:  Karen M Ong; Michael S Phillips; Charles S Peskin
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240

6.  Validation and Extrapolation of a Multimodal Infection Prevention and Control Intervention on Carbapenem-Resistant Klebsiella pneumoniae in an Epidemic Region: A Historical Control Quasi-Experimental Study.

Authors:  Yunqi Dai; Tianjiao Meng; Xiaoli Wang; Bin Tang; Feng Wang; Ying Du; Yuzhen Qiu; Jialin Liu; Ruoming Tan; Hongping Qu
Journal:  Front Med (Lausanne)       Date:  2021-07-07

7.  Epidemiology of Carbapenem-Resistant Enterobacteriaceae at a Long-term Acute Care Hospital.

Authors:  Teena Chopra; Christopher Rivard; Reda A Awali; Amar Krishna; Robert A Bonomo; Federico Perez; Keith S Kaye
Journal:  Open Forum Infect Dis       Date:  2018-10-03       Impact factor: 3.835

8.  Evaluation of the Association Between Gastric Acid Suppression and Risk of Intestinal Colonization With Multidrug-Resistant Microorganisms: A Systematic Review and Meta-analysis.

Authors:  Roel P J Willems; Karin van Dijk; Johannes C F Ket; Christina M J E Vandenbroucke-Grauls
Journal:  JAMA Intern Med       Date:  2020-04-01       Impact factor: 21.873

9.  Epidemiological and Microbiome Associations Between Klebsiella pneumoniae and Vancomycin-Resistant Enterococcus Colonization in Intensive Care Unit Patients.

Authors:  Abigail Collingwood; Freida Blostein; Anna M Seekatz; Christiane E Wobus; Robert J Woods; Betsy Foxman; Michael A Bachman
Journal:  Open Forum Infect Dis       Date:  2020-01-12       Impact factor: 3.835

10.  The importance of active surveillance of carbapenem-resistant Enterobacterales (CRE) in colonization rates in critically ill patients.

Authors:  Mabel Duarte Alves Gomides; Astrídia Marília de Souza Fontes; Amanda Oliveira Soares Monteiro Silveira; Daniel Chadud Matoso; Anderson Luiz Ferreira; Geraldo Sadoyama
Journal:  PLoS One       Date:  2022-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.